AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16427529 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 56
Study 12873935 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine 0.2 mg/kg followed by propofol infusion
Number of subjects: 67
Study 12873935 — intervention group
Group type: COMPARATOR
Intervention: IV normal saline (placebo) followed by propofol 1%/lidocaine 1% mixture infusion
Number of subjects: 67
Study 10469680 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic diagnosis (PGD) for aneuploidy
Number of subjects: 0
Study 10469680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGD)
Number of subjects: 0
Study 8915224 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ANP (3 pmol/kg/min)
Number of subjects: 8
Study 8915224 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose BNP (3 pmol/kg/min)
Number of subjects: 8
Study 8915224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ANP (10 pmol/kg/min)
Number of subjects: 8
Study 8915224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose BNP (10 pmol/kg/min)
Number of subjects: 8
Study 8915224 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ANP
Number of subjects: 8
Study 8915224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ANP
Number of subjects: 8
Study 8915224 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose BNP
Number of subjects: 8
Study 8915224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose BNP
Number of subjects: 8
Study 1860210 — intervention group
Group type: COMPARATOR
Intervention: Biphasic waveform defibrillation (epicardial RV-LV system)
Number of subjects: 51
Study 1860210 — intervention group
Group type: COMPARATOR
Intervention: Biphasic waveform defibrillation (nonthoracotomy RV-CP system)
Number of subjects: 51
Study 1860210 — intervention group
Group type: COMPARATOR
Intervention: Biphasic waveform defibrillation (nonthoracotomy CS-RV system)
Number of subjects: 51
Study 1860210 — intervention group
Group type: COMPARATOR
Intervention: Biphasic waveform defibrillation (RV-LV epicardial patches)
Number of subjects: 51
Study 1860210 — intervention group
Group type: COMPARATOR
Intervention: Biphasic waveform defibrillation (RV-CP nonthoracotomy system)
Number of subjects: 51
Study 1860210 — intervention group
Group type: COMPARATOR
Intervention: Biphasic waveform defibrillation (RV-CS nonthoracotomy system)
Number of subjects: 51
Study 6341017 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximized insulin treatment
Number of subjects: 0
Study 6341017 — intervention group
Group type: COMPARATOR
Intervention: Standard control
Number of subjects: 0
Study 30796909 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid arch bars
Number of subjects: 90
Study 30796909 — intervention group
Group type: COMPARATOR
Intervention: Erich arch bars
Number of subjects: 90
Study 30551315 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT) + psychoeducation
Number of subjects: 49
Study 30551315 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation + Metacognitive training (MCT)
Number of subjects: 49
Study 26792933 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg twice a day for 24 weeks
Number of subjects: 54
Study 24557078 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir-containing regimens
Number of subjects: 542
Study 24557078 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline bilirubin level of 0.5 mg/dl or higher with hemoglobin concentrations of 14 g/dl or higher
Number of subjects: 542
Study 24557078 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline bilirubin level <0.5 mg/dl with hemoglobin concentration <14 g/dl
Number of subjects: 542
Study 22897752 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day)
Number of subjects: 372
Study 22897752 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel (AUC 5/6; 200 mg/m(2))
Number of subjects: 372
Study 19335497 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental perioperative oxygenation
Number of subjects: 4
Study 19335497 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4
Study 17690808 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent positive social support
Number of subjects: 1726
Study 17690808 — intervention group
Group type: COMPARATOR
Intervention: Negative social support
Number of subjects: 1726
Study 17690808 — intervention group
Group type: COMPARATOR
Intervention: Limited positive social support
Number of subjects: 1726
Study 15576543 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative multifaceted strategy combining written comparative feedback, group education on national guidelines, and social influence by peers in quality improvement sessions in small groups.
Number of subjects: 194
Study 15576543 — intervention group
Group type: COMPARATOR
Intervention: Feedback only
Number of subjects: 194
Study 15576543 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative multifaceted strategy
Number of subjects: 194
Study 11457553 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV/Hib vaccine administered as a single injection (Group 1)
Number of subjects: 885
Study 11457553 — intervention group
Group type: COMPARATOR
Intervention: DTPa-HBV and Hib vaccines administered simultaneously at separate sites (Group 2)
Number of subjects: 885
Study 11457553 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 885
Study 9734938 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF alpha MAb (7.5 mg/kg)
Number of subjects: 1879
Study 9734938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.25% human serum albumin)
Number of subjects: 1879
Study 9734938 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF alpha MAb
Number of subjects: 1879
Study 9734938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1879
Study 7802530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (Iox), an ionic product
Number of subjects: 64
Study 7802530 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol (Iop), a non-ionic product
Number of subjects: 64
Study 3289293 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 45
Study 3289293 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple insulin injections
Number of subjects: 45
Study 3289293 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (twice daily injections)
Number of subjects: 45
Study 29956440 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical EGF ointment
Number of subjects: 19
Study 29956440 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum (Control)
Number of subjects: 19
Study 26628069 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG) - Auditory training program using a mobile device for 4 weeks
Number of subjects: 20
Study 26628069 — intervention group
Group type: COMPARATOR
Intervention: Control Group (NTG) - Traditional auditory training for 4 weeks
Number of subjects: 20
Study 26628069 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG) - Auditory training program using a mobile device
Number of subjects: 20
Study 26628069 — intervention group
Group type: COMPARATOR
Intervention: Control Group (NTG) - Traditional auditory training
Number of subjects: 20
Study 26583667 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT-EOS >3 mmol/L
Number of subjects: 985
Study 26583667 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT-EOS cutoff values
Number of subjects: 985
Study 23921427 — intervention group
Group type: EXPERIMENTAL
Intervention: BOSU trainer
Number of subjects: 57
Study 23921427 — intervention group
Group type: EXPERIMENTAL
Intervention: Airex balance pad
Number of subjects: 57
Study 23921427 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-foam roller
Number of subjects: 57
Study 23921427 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaDisc
Number of subjects: 57
Study 21030168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa
Number of subjects: 5
Study 21030168 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (normal saline)
Number of subjects: 5
Study 21030168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa and 0.9% NaCl
Number of subjects: 5
Study 19674280 — intervention group
Group type: EXPERIMENTAL
Intervention: Human intravenous immunoglobulin (hIVIG) 0.5 g/kg
Number of subjects: 18
Study 19674280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16989922 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-detector multi-slice CT screening for lung cancer
Number of subjects: 0
Study 16989922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study 12892536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy
Number of subjects: 0
Study 12892536 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 12892536 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 0
Study 12892536 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0
Study 12892536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 0
Study 12892536 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 10931101 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose short synacthen test (HDT, 250 microgram)
Number of subjects: 30
Study 10931101 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose short synacthen test (LDT, 1 microgram)
Number of subjects: 30
Study 10931101 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test (ITT)
Number of subjects: 30
Study 9065962 — intervention group
Group type: EXPERIMENTAL
Intervention: WS 1490 (kava-kava extract)
Number of subjects: 101
Study 9065962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 8147961 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc + Vitamin A
Number of subjects: 140
Study 8147961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 8147961 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (25 mg/d)
Number of subjects: 140
Study 8147961 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (1500 mg RE/d)
Number of subjects: 140
Study 3092269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 30 mg
Number of subjects: 12
Study 3092269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 100 mg
Number of subjects: 12
Study 3092269 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg
Number of subjects: 12
Study 3092269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31718953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 33
Study 31718953 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 3.75 mg once daily
Number of subjects: 33
Study 30340503 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise intervention (moderate-vigorous, 65-85% heart rate maximum, thrice weekly for 16 weeks)
Number of subjects: 100
Study 30340503 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise intervention
Number of subjects: 100
Study 27346807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine
Number of subjects: 76
Study 27346807 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal saline
Number of subjects: 76
Study 24758077 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut implantation at acupoint for 3 months
Number of subjects: 74
Study 24758077 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine Enteric-coated Tablet (SECT), 0.5 g three times daily for 3 months (Control)
Number of subjects: 74
Study 23047470 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of ciprofloxacin 500 mg
Number of subjects: 24
Study 23047470 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of ciprofloxacin 500 mg
Number of subjects: 24
Study 20547163 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 101
Study 20547163 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (up to 320 mg/day)
Number of subjects: 101
Study 17340594 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen suppression therapy (AST) and radiation therapy (RT) with 70 Gy and 6 months of AST
Number of subjects: 102
Study 17340594 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing PSA level
Number of subjects: 102
Study 17340594 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason score 8-10 cancer
Number of subjects: 102
Study 15827107 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.5 mg/d)
Number of subjects: 12
Study 15827107 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (250 mg)
Number of subjects: 12
Study 15827107 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.5 mg/d) and Testosterone (250 mg) combined
Number of subjects: 12
Study 15827107 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study 12474916 — intervention group
Group type: COMPARATOR
Intervention: Modified fluorescein dye disappearance test (DDT) with 2% fluorescein instilled in the eye; Schirmer tear test strips placed in the lower conjunctival fornix after 3 and 10 minutes.
Number of subjects: 74
Study 9865428 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (1.01 mg/kg/day)
Number of subjects: 12
Study 9865428 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (2.01 mg/kg/day)
Number of subjects: 12
Study 9865428 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0.16 mg/kg/day)
Number of subjects: 12
Study 7885123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral captopril (6.25 mg initial dose, 12.5 mg 2 hours later, and then 12.5 mg three times daily)
Number of subjects: 13634
Study 7885123 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 13634
Study 7885123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral captopril
Number of subjects: 13634
Study 2195936 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily (OD) theophylline therapy administered in the evening at 8:00 P.M.
Number of subjects: 0
Study 2195936 — intervention group
Group type: COMPARATOR
Intervention: Conventional twice-daily (TD) theophylline therapy administered at 8:00 A.M. and 8:00 P.M.
Number of subjects: 0
Study 484815 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal analgesia (1.5 mg/kg bupivacaine)
Number of subjects: 40
Study 484815 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine (0.15 mg/kg)
Number of subjects: 40
Study 31073952 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass (RYGB)
Number of subjects: 45
Study 28561068 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (35 mg/kg p.o.)
Number of subjects: 17
Study 25887977 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated treatment with praziquantel and albendazole four times a year
Number of subjects: 765
Study 25887977 — intervention group
Group type: COMPARATOR
Intervention: Single dose treatment with praziquantel and albendazole once a year
Number of subjects: 765
Study 22959782 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load strength training with protein supplementation
Number of subjects: 29
Study 22959782 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load strength training with nonprotein supplementation
Number of subjects: 29
Study 22959782 — intervention group
Group type: COMPARATOR
Intervention: Control period (no training)
Number of subjects: 29
Study 21475970 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 57
Study 21475970 — intervention group
Group type: COMPARATOR
Intervention: Bupropion (300 mg/day)
Number of subjects: 57
Study 21475970 — intervention group
Group type: COMPARATOR
Intervention: Non-Contingent Reinforcement (NR)
Number of subjects: 57
Study 21475970 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including CM and NR)
Number of subjects: 57
Study 19575051 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamide polymer burs
Number of subjects: 40
Study 19575051 — intervention group
Group type: COMPARATOR
Intervention: Carbon steel round burs
Number of subjects: 40
Study 17724558 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy twice a week for 4 weeks followed by stretching exercises
Number of subjects: 125
Study 17724558 — intervention group
Group type: COMPARATOR
Intervention: Stretching 5 times a week for 4 weeks followed by manual therapy
Number of subjects: 125
Study 16202254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine tablet (10-20 mg/day for 24 weeks)
Number of subjects: 359
Study 16202254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine capsule (10-20 mg/day for 24 weeks)
Number of subjects: 359
Study 16202254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 12456942 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 51
Study 12456942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11783214 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodongining (DDN)
Number of subjects: 70
Study 11783214 — intervention group
Group type: COMPARATOR
Intervention: Ritalin
Number of subjects: 70
Study 9213594 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser flare meter (Kowa FM-500) used for monitoring
Number of subjects: 50
Study 9213594 — intervention group
Group type: COMPARATOR
Intervention: Postoperative period after uncomplicated keratoplasty
Number of subjects: 50
Study 9213594 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute allograft rejection treatment
Number of subjects: 50
Study 2012051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine administration
Number of subjects: 35
Study 2012051 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine non-administration (Control)
Number of subjects: 35
Study 6165217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0
Study 6165217 — intervention group
Group type: COMPARATOR
Intervention: Untreated women (control group)
Number of subjects: 0
Study 30747394 — intervention group
Group type: EXPERIMENTAL
Intervention: SDPI‐DP lifestyle intervention
Number of subjects: 0
Study 30747394 — intervention group
Group type: COMPARATOR
Intervention: Historical control (Diabetes Prevention Program placebo group)
Number of subjects: 0
Study 27842422 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-laser imaging (BLI)
Number of subjects: 127
Study 27842422 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 127
Study 26418019 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 905
Study 26418019 — intervention group
Group type: COMPARATOR
Intervention: Losartan-based treatment
Number of subjects: 905
Study 23829442 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary educational group workshop including didactic lectures, value-clarification exercise, and patient discussions.
Number of subjects: 30
Study 23829442 — intervention group
Group type: COMPARATOR
Intervention: Usual care (informational booklet, website, patient volunteer if desired).
Number of subjects: 30
Study 22962420 — intervention group
Group type: EXPERIMENTAL
Intervention: MES-guided placement of RV lead
Number of subjects: 50
Study 22962420 — intervention group
Group type: COMPARATOR
Intervention: Standard apical placement of RV lead
Number of subjects: 50
Study 20183664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 439
Study 20183664 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 439
Study 20183664 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and FLX
Number of subjects: 439
Study 20183664 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 439
Study 20183664 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (CBT, FLX, Combination, Placebo)
Number of subjects: 439
Study 17576024 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 21
Study 17576024 — intervention group
Group type: COMPARATOR
Intervention: PSV23
Number of subjects: 21
Study 15182114 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan therapy (40-80 mg once daily)
Number of subjects: 0
Study 15182114 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study 12455252 — intervention group
Group type: EXPERIMENTAL
Intervention: Family medicine preceptor
Number of subjects: 464
Study 12455252 — intervention group
Group type: EXPERIMENTAL
Intervention: General internal medicine preceptor
Number of subjects: 464
Study 12455252 — intervention group
Group type: COMPARATOR
Intervention: Generalist experiences during medical school
Number of subjects: 464
Study 11477811 — intervention group
Group type: EXPERIMENTAL
Intervention: DF-521 with Heart-Brain Mixture (HBM)
Number of subjects: 66
Study 11477811 — intervention group
Group type: COMPARATOR
Intervention: DF-521 alone
Number of subjects: 66
Study 11477811 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 66
Study 7653792 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (1.0 mg/kg)
Number of subjects: 20
Study 7653792 — intervention group
Group type: EXPERIMENTAL
Intervention: R80122 (0.3 mg/kg)
Number of subjects: 20
Study 2702910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia (50 mg/dl)
Number of subjects: 18
Study 2702910 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia (100 mg/dl)
Number of subjects: 18
Study 2702910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (300 mg/dl)
Number of subjects: 18
Study 362207 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (400 to 800 micrograms per day in divided doses)
Number of subjects: 20
Study 362207 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day prednisone (20 to 40 mg on alternate mornings)
Number of subjects: 20
Study 362207 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate and alternate-day prednisone (used together)
Number of subjects: 20